Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers.
Pear Therapeutics became a publicly listed company on December 3, 2021 after completing a business combination with Thimble Point Acquisition, a publicly traded special purpose acquisition company. Forge no longer actively tracks this company.
